Chemoprevention of malaria with long-acting oral and injectable drugs: an updated target product profile.
Chemoprevention
Drug development
Malaria
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
18 Oct 2024
18 Oct 2024
Historique:
received:
08
05
2024
accepted:
03
10
2024
medline:
19
10
2024
pubmed:
19
10
2024
entrez:
18
10
2024
Statut:
epublish
Résumé
Malaria is preventable, but the burden of disease remains high with over 249 million cases and 608,000 deaths reported in 2022. Historically, the most important protective interventions have been vector control and chemopreventive medicines with over 50 million children receiving seasonal malaria chemoprevention in the year 2023. Two vaccines are approved and starting to be deployed, bringing additional protection for children up to 36 months. However, the impact of these currently available tools is somewhat limited on various fronts. Vaccines exhibit partial efficacy, are relatively costly, and not accessible in all settings. The challenges encountered with chemoprevention are barriers to acceptability and feasibility, including frequency of dosing, and the lack of options in the first trimester of pregnancy and for women living with HIV. Also, the emergence of resistance against chemopreventive medicines is concerning. To address these limitations, a target product profile (TPP) is proposed as a road map to guide innovation and to boost the quest for novel chemopreventive alternatives. This TPP describes the ideal product attributes, while acknowledging potential trade-offs that may be needed. Critically, it considers the target populations most at risk; primarily infants, children, and pregnant women. Malaria control and elimination requires appropriate chemoprevention, not only in areas of high endemicity and transmission, but also in lower transmission areas where immunity is declining, as well as for travellers from areas where malaria has been eliminated. New medicines should show acceptable safety and tolerability, with high and long protective efficacy. Formulations and costs need to support operational adherence, access, and effectiveness. Next generation long-acting oral and injectable drugs are likely to constitute the backbone of malaria prevention. Therefore, the perspectives of front-line experts in malaria prevention, researchers, and those involved in drug development are captured in the TPP. This inclusive approach aims at concentrating efforts and aligning responses across the community to develop new and transformative medicines.
Identifiants
pubmed: 39425110
doi: 10.1186/s12936-024-05128-1
pii: 10.1186/s12936-024-05128-1
doi:
Substances chimiques
Antimalarials
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
315Informations de copyright
© 2024. The Author(s).
Références
WHO. World malaria report. Geneva, World Health Organization, 2023. https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2023 . Accessed: 19 April 2024.
WHO. Guidelines for malaria. Geneva, World Health Organization, 2023. https://www.who.int/publications/i/item/guidelines-for-malaria . Accessed: 19 April 2024.
malERA Refresh Consultative Panel on Tools for Malaria Elimination. malERA: an updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication. PLoS Med. 2017;14:e1002455.
doi: 10.1371/journal.pmed.1002455
Brooks DR, Wang P, Read M, Watkins WM, Sims PF, Hyde JE. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur J Biochem. 1994;224:397–405.
pubmed: 7925353
doi: 10.1111/j.1432-1033.1994.00397.x
Foote SJ, Galatis D, Cowman AF. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc Natl Acad Sci USA. 1990;87:3014–7.
pubmed: 2183221
pmcid: 53824
doi: 10.1073/pnas.87.8.3014
Cohen O, Guemas E, Menard S, Tsague Kenfack M, Talom Ngassa C, Iriart X, et al. Effect of sulfadoxine-pyrimethamine chemoprophylaxis in pregnant women on selection of the new P. falciparum dhps quintuple mutant carrying the I431V mutation. J Antimicrob Chemother. 2023;78:665–8.
pubmed: 36611259
doi: 10.1093/jac/dkac432
Gutman J, Kalilani L, Taylor S, Zhou Z, Wiegand RE, Thwai KL, et al. The A581G mutation in the gene encoding Plasmodium falciparum dihydropteroate synthetase reduces the effectiveness of sulfadoxine-pyrimethamine preventive therapy in Malawian pregnant women. J Infect Dis. 2015;211:1997–2005.
pubmed: 25564249
pmcid: 4539907
doi: 10.1093/infdis/jiu836
World Health Organization. WHO recommends R21/Matrix-M vaccine for malaria prevention in updated advice on immunization. Geneva, World Health Organization, 2023. https://www.who.int/news/item/02-10-2023-who-recommends-r21-matrix-m-vaccine-for-malaria-prevention-in-updated-advice-on-immunization . Accessed: 19 April 2024.
Moorthy V, Hamel MJ, Smith PG. Malaria vaccines for children: and now there are two. Lancet. 2024;403:504–5.
pubmed: 38310911
doi: 10.1016/S0140-6736(23)02743-5
Aderinto N, Olatunji G, Kokori E, Sikirullahi S, Aboje JE, Ojabo RE. A perspective on Oxford’s R21/Matrix-M malaria vaccine and the future of global eradication efforts. Malar J. 2024;23:16.
pubmed: 38216923
pmcid: 10787413
doi: 10.1186/s12936-024-04846-w
Adepoju P. Routine malaria vaccinations begin. Lancet. 2024;403:423.
pubmed: 38310887
doi: 10.1016/S0140-6736(24)00194-6
Asante KP, Mathanga DP, Milligan P, Akech S, Oduro A, Mwapasa V, et al. Feasibility, safety, and impact of the RTS,S/AS01(E) malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi. Lancet. 2024;S0140-6736(24)00004-7:Online ahead of print.
Amimo F. Malaria vaccination: hurdles to reach high-risk children. BMC Med. 2024;22:111.
pubmed: 38475775
pmcid: 10935779
doi: 10.1186/s12916-024-03321-2
Nnaji CA, Amaechi UA, Wiysonge CS. R21/Matrix-M vaccine: optimising supply, maximising impact. Lancet. 2024;403:525.
pubmed: 38341243
doi: 10.1016/S0140-6736(23)02716-2
Oduoye MO, Haider MU, Marsool MDM, Kareem MO, Adedayo AE, Abdulkarim AS, et al. Unlocking the potential of novel RTS, S/AS01, and R21/Matrix-M malaria vaccines in African nations. Health Sci Rep. 2024;7: e1797.
pubmed: 38186933
pmcid: 10766872
doi: 10.1002/hsr2.1797
Saaka SA, Mohammed K, C KAP, Luginaah I. Child malaria vaccine uptake in Ghana: factors influencing parents' willingness to allow vaccination of their children under five (5) years. PLoS One. 2024;19:e0296934.
Simbeye AJ, Kumwenda S, Cohee LM, Omondi D, Masibo PK, Wao H, et al. Factors associated with malaria vaccine uptake in Nsanje district, Malawi. Malar J. 2024;23:105.
pubmed: 38627704
pmcid: 11022426
doi: 10.1186/s12936-024-04938-7
Dobbs KR, Atieli HE, Valim C, Beeson JG. Previous malaria exposures and immune dysregulation: developing strategies to improve malaria vaccine efficacy in young children. Am J Trop Med Hyg. 2024;110:627–30.
pubmed: 38442424
doi: 10.4269/ajtmh.23-0696
Olotu A, Fegan G, Wambua J, Nyangweso G, Leach A, Lievens M, et al. Seven-year efficacy of RTS, S/AS01 malaria vaccine among young African children. N Engl J Med. 2016;374:2519–29.
pubmed: 27355532
pmcid: 4962898
doi: 10.1056/NEJMoa1515257
Dicko A, Ouedraogo JB, Zongo I, Sagara I, Cairns M, Yerbanga RS, et al. Seasonal vaccination with RTS, S/AS01(E) vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial. Lancet Infect Dis. 2024;24:75–86.
pubmed: 37625434
doi: 10.1016/S1473-3099(23)00368-7
Dutta S, Thera MA. Seasonal RTS, S/AS01(E) vaccination with or without seasonal malaria chemoprevention. Lancet Infect Dis. 2024;24:9–11.
pubmed: 37625433
doi: 10.1016/S1473-3099(23)00392-4
El Gaaloul M, Tornesi B, Lebus F, Reddy D, Kaszubska W. Re-orienting anti-malarial drug development to better serve pregnant women. Malar J. 2022;21:121.
pubmed: 35413907
pmcid: 9003153
doi: 10.1186/s12936-022-04137-2
Addy JWG, Bediako Y, Ndungu FM, Valetta JJ, Reid AJ, Mwacharo J, et al. 10-year longitudinal study of malaria in children: Insights into acquisition and maintenance of naturally acquired immunity. Wellcome Open Res. 2021;6:79.
pubmed: 35141425
doi: 10.12688/wellcomeopenres.16562.2
Greenwood B, Zongo I, Dicko A, Chandramohan D, Snow RW, Ockenhouse C. Resurgent and delayed malaria. Malar J. 2022;21:77.
pubmed: 35264158
pmcid: 8905818
doi: 10.1186/s12936-022-04098-6
Konate D, Diawara SI, Sogoba N, Shaffer J, Keita B, Cisse A, et al. Effect of a fifth round of seasonal malaria chemoprevention in children aged 5–14 years in Dangassa, an area of long transmission in Mali. Parasite Epidemiol Control. 2023;20: e00283.
pubmed: 36704118
pmcid: 9871299
doi: 10.1016/j.parepi.2022.e00283
Diawara SI, Konate D, Kayentao K, Mihigo J, Shaffer JG, Sangare M, et al. Effect of seasonal malaria chemoprevention in children between 5 and 9 years old in Kita and Bafoulabe districts, Mali. Parasite Epidemiol Control. 2022;18: e00258.
pubmed: 35789762
pmcid: 9249800
doi: 10.1016/j.parepi.2022.e00258
Suh E, Stopard IJ, Lambert B, Waite JL, Dennington NL, Churcher TS, et al. Estimating the effects of temperature on transmission of the human malaria parasite Plasmodium falciparum. Nat Commun. 2024;15:3230.
pubmed: 38649361
pmcid: 11035611
doi: 10.1038/s41467-024-47265-w
Yu Q, Qu Y, Zhang L, Yao X, Yang J, Chen S, et al. Spatial spillovers of violent conflict amplify the impacts of climate variability on malaria risk in sub-Saharan Africa. Proc Natl Acad Sci USA. 2024;121: e2309087121.
pubmed: 38557184
pmcid: 11009658
doi: 10.1073/pnas.2309087121
Obame-Nkoghe J, Agossou AE, Mboowa G, Kamgang B, Caminade C, Duke DC, et al. Climate-influenced vector-borne diseases in Africa: a call to empower the next generation of African researchers for sustainable solutions. Infect Dis Poverty. 2024;13:26.
pubmed: 38486340
pmcid: 10938833
doi: 10.1186/s40249-024-01193-5
Kaseya J, Dereje N, Tajudeen R, Ngongo AN, Ndembi N, Fallah MP. Climate change and malaria, dengue and cholera outbreaks in Africa: a call for concerted actions. BMJ Glob Health. 2024;9: e015370.
pubmed: 38453519
pmcid: 10921484
doi: 10.1136/bmjgh-2024-015370
Audibert C, Tchouatieu AM. Perception of malaria chemoprevention interventions in infants and children in eight sub-saharan African countries: an end user perspective study. Trop Med Infect Dis. 2021;6:75.
pubmed: 34064620
pmcid: 8163176
doi: 10.3390/tropicalmed6020075
Gatiba P, Laury J, Steinhardt L, Hwang J, Thwing JI, Zulliger R, et al. Contextual factors to improve implementation of malaria chemoprevention in children: a systematic review. Am J Trop Med Hyg. 2024;110:69–78.
pubmed: 38081055
doi: 10.4269/ajtmh.23-0478
Cairns M, Ceesay SJ, Sagara I, Zongo I, Kessely H, Gamougam K, et al. Effectiveness of seasonal malaria chemoprevention (SMC) treatments when SMC is implemented at scale: case-control studies in 5 countries. PLoS Med. 2021;18: e1003727.
pubmed: 34495978
pmcid: 8457484
doi: 10.1371/journal.pmed.1003727
Meremikwu MM, Donegan S, Sinclair D, Esu E, Oringanje C. Intermittent preventive treatment for malaria in children living in areas with seasonal transmission. Cochrane Database Syst Rev. 2012;2012:CD003756.
pubmed: 22336792
pmcid: 6532713
Yaro JB, Tiono AB, Ouedraogo A, Lambert B, Ouedraogo ZA, Diarra A, et al. Risk of Plasmodium falciparum infection in south-west Burkina Faso: potential impact of expanding eligibility for seasonal malaria chemoprevention. Sci Rep. 2022;12:1402.
pubmed: 35082312
pmcid: 8791962
doi: 10.1038/s41598-022-05056-7
Ndiaye JLA, Ndiaye Y, Ba MS, Faye B, Ndiaye M, Seck A, et al. Seasonal malaria chemoprevention combined with community case management of malaria in children under 10 years of age, over 5 months, in south-east Senegal: a cluster-randomised trial. PLoS Med. 2019;16: e1002762.
pubmed: 30865632
pmcid: 6415816
doi: 10.1371/journal.pmed.1002762
Wharton-Smith A, Baker K, Roca-Feltrer A, Rodrigues M, Richardson S, Bonnington CA, et al. Assessment of the feasibility, acceptability, and impact of implementing seasonal malaria chemoprevention in Nampula Province, Mozambique: protocol for a hybrid effectiveness-implementation study. JMIR Res Protoc. 2021;10: e27855.
pubmed: 34524109
pmcid: 8482168
doi: 10.2196/27855
Nuwa A, Baker K, Bonnington C, Odongo M, Kyagulanyi T, Bwanika JB, et al. A non-randomized controlled trial to assess the protective effect of SMC in the context of high parasite resistance in Uganda. Malar J. 2023;22:63.
pubmed: 36814301
pmcid: 9945593
doi: 10.1186/s12936-023-04488-4
Molina-de la Fuente I, Sagrado Benito MJ, Lasry E, Ousley J, Garcia L, Gonzalez V, et al. Seasonal malaria chemoprevention in a context of high presumed sulfadoxine-pyrimethamine resistance: malaria morbidity and molecular drug resistance profiles in South Sudan. Malar J. 2023;22:345.
pubmed: 37950227
pmcid: 10637007
doi: 10.1186/s12936-023-04740-x
Wang X, Zhang X, Chen H, Lu Q, Ruan W, Chen Z. Molecular determinants of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum isolates from central Africa between 2016 and 2021: wide geographic spread of highly mutated Pfdhfr and Pfdhps alleles. Microbiol Spectr. 2022;10: e0200522.
pubmed: 36121226
doi: 10.1128/spectrum.02005-22
Flegg JA, Humphreys GS, Montanez B, Strickland T, Jacome-Meza ZJ, Barnes KI, et al. Spatiotemporal spread of Plasmodium falciparum mutations for resistance to sulfadoxine-pyrimethamine across Africa, 1990–2020. PLoS Comput Biol. 2022;18: e1010317.
pubmed: 35951528
pmcid: 9371298
doi: 10.1371/journal.pcbi.1010317
Ndiaye YD, Wong W, Thwing J, Schaffner SS, Tine A, Diallo MA, et al. Two decades of molecular surveillance in Senegal reveal changes in known drug resistance mutations associated with historical drug use and seasonal malaria chemoprevention. medRxiv. 2023;04.24.23288820.
Plowe CV. Malaria chemoprevention and drug resistance: a review of the literature and policy implications. Malar J. 2022;21:104.
pubmed: 35331231
pmcid: 8943514
doi: 10.1186/s12936-022-04115-8
Braunack-Mayer L, Malinga J, Masserey T, Nekkab N, Sen S, Schellenberg D, et al. Design and selection of drug properties to increase the public health impact of next-generation seasonal malaria chemoprevention: a modelling study. Lancet Glob Health. 2024;12:e478–90.
pubmed: 38365418
pmcid: 10882206
doi: 10.1016/S2214-109X(23)00550-8
Zongo I, Compaore YD. Seasonal malaria chemoprevention: drug design and selection. Lancet Glob Health. 2024;12:e358–9.
pubmed: 38365403
doi: 10.1016/S2214-109X(24)00011-1
Rogerson SJ, Unger HW. Pregnancy and malaria: the perfect storm. Curr Opin Infect Dis. 2022;35:410–6.
pubmed: 35916532
doi: 10.1097/QCO.0000000000000859
Aberese-Ako M, Doegah P, Acquah E, Magnussen P, Ansah E, Ampofo G, et al. Motivators and demotivators to accessing malaria in pregnancy interventions in sub-Saharan Africa: a meta-ethnographic review. Malar J. 2022;21:170.
pubmed: 35659232
pmcid: 9166609
doi: 10.1186/s12936-022-04205-7
Darteh EKM, Dickson KS, Ahinkorah BO, Owusu BA, Okyere J, Salihu T, et al. Factors influencing the uptake of intermittent preventive treatment among pregnant women in sub-Saharan Africa: a multilevel analysis. Arch Public Health. 2021;79:182.
pubmed: 34670628
pmcid: 8529836
doi: 10.1186/s13690-021-00707-z
Roman E, Andrejko K, Wolf K, Henry M, Youll S, Florey L, et al. Determinants of uptake of intermittent preventive treatment during pregnancy: a review. Malar J. 2019;18:372.
pubmed: 31752868
pmcid: 6873519
doi: 10.1186/s12936-019-3004-7
Dun-Dery F, Meissner P, Beiersmann C, Kuunibe N, Winkler V, Albrecht J, et al. Uptake challenges of intermittent preventive malaria therapy among pregnant women and their health care providers in the Upper West Region of Ghana: a mixed-methods study. Parasite Epidemiol Control. 2021;15: e00222.
pubmed: 34632123
pmcid: 8488310
doi: 10.1016/j.parepi.2021.e00222
Cardona-Arias JA. Synthesis of qualitative evidence on malaria in pregnancy, 2005–2022: a systematic review. Trop Med Infect Dis. 2023;8:235.
pubmed: 37104360
pmcid: 10145031
doi: 10.3390/tropicalmed8040235
Rassi C, Graham K, Mufubenga P, King R, Meier J, Gudoi SS. Assessing supply-side barriers to uptake of intermittent preventive treatment for malaria in pregnancy: a qualitative study and document and record review in two regions of Uganda. Malar J. 2016;15:341.
pubmed: 27377538
pmcid: 4932731
doi: 10.1186/s12936-016-1405-4
WHO. Community deployment of intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine a field guide. Geneva, World Health Organization, 2024. https://www.who.int/publications/i/item/9789240086272 . Accessed: 19 April, 2024.
Macintyre F, Ramachandruni H, Burrows JN, Holm R, Thomas A, Mohrle JJ, et al. Injectable anti-malarials revisited: discovery and development of new agents to protect against malaria. Malar J. 2018;17:402.
pubmed: 30384848
pmcid: 6211409
doi: 10.1186/s12936-018-2549-1
Durham SH, Milam A, Waer D, Chahine EB. Cabotegravir: the first long-acting injectable for HIV preexposure prophylaxis. Ann Pharmacother. 2023;57:306–16.
pubmed: 35778802
doi: 10.1177/10600280221102532
Parums DV. Editorial: the first monoclonal antibody vaccine to prevent malaria heralds a new era of malaria vaccines to the Plasmodium falciparum circumsporozoite protein (PfCSP). Med Sci Monit. 2021;27: e934676.
pubmed: 34511592
pmcid: 8447852
doi: 10.12659/MSM.934676
Moehrle JJ. Development of new strategies for malaria chemoprophylaxis: from monoclonal antibodies to long-acting injectable drugs. Trop Med Infect Dis. 2022;7:58.
pubmed: 35448833
pmcid: 9024890
doi: 10.3390/tropicalmed7040058
Kayentao K, Ongoiba A, Preston AC, Healy SA, Hu Z, Skinner J, et al. Subcutaneous administration of a monoclonal antibody to prevent malaria. N Engl J Med. 2024;390:1549–59.
pubmed: 38669354
doi: 10.1056/NEJMoa2312775
Wells T, Donini C. Monoclonal antibodies for malaria. N Engl J Med. 2022;387:462–5.
pubmed: 35921457
doi: 10.1056/NEJMe2208131
Burrows JN, Duparc S, Gutteridge WE, Hooft van Huijsduijnen R, Kaszubska W, Macintyre F, et al. New developments in anti-malarial target candidate and product profiles. Malar J. 2017;16:26.
pubmed: 28086874
pmcid: 5237200
doi: 10.1186/s12936-016-1675-x
WHO. Malaria chemoprevention: preferred product characteristics. Geneva, World Health Organization, 2023. https://www.who.int/publications/i/item/9789240070967 . Accessed: 19 April, 2024.
World Health Organization. WHO technical consultation on preferred product characteristics for drugs used in malaria chemoprevention: meeting report, 15–16 December 2020. Geneva, World Health Organization, 2022. https://www.who.int/publications/i/item/9789240059016 . Accessed: 22 March, 2023.
WHO. Monoclonal antibodies for malaria prevention: preferred product characteristics and clinical development considerations. Geneva, World Health Organization, 2023. https://www.who.int/publications/i/item/9789240070981 . Accessed: 22 April, 2024.
Zongo I, Milligan P, Compaore YD, Some AF, Greenwood B, Tarning J, et al. Randomized noninferiority trial of dihydroartemisinin-piperaquine compared with sulfadoxine-pyrimethamine plus amodiaquine for seasonal malaria chemoprevention in Burkina Faso. Antimicrob Agents Chemother. 2015;59:4387–96.
pubmed: 25918149
pmcid: 4505196
doi: 10.1128/AAC.04923-14
Malaria Vaccine Implementation Programme Advisory Group, Strategic Advisory Group of Experts on Immunization, Malaria Policy Advisory Group. Full evidence report on the RTS,S/AS01 malaria vaccine. Geneva, World Health Organization, 2021. https://cdn.who.int/media/docs/default-source/immunization/mvip/full-evidence-report-on-the-rtss-as01-malaria-vaccine-for-sage-mpag-(sept2021).pdf?sfvrsn=c9737be_5 . Accessed: 14 March, 2023.
Datoo MS, Dicko A, Tinto H, Ouedraogo JB, Hamaluba M, Olotu A, et al. Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet. 2024;403:533–44.
pubmed: 38310910
doi: 10.1016/S0140-6736(23)02511-4
The Global Fund. Price reference report: price list. Geneva, The Global Fund to Fight AIDS, Tuperculosis and Malaria; 2024. https://insights.theglobalfund.org/t/Public/views/PriceQualityReportingPriceReferenceReport/PriceList . Accessed: 22 April, 2024.
GAVI, the vaccine alliance. Shipments to African countries herald final steps toward broader vaccination against malaria. Geneva, GAVI; 2024. https://www.gavi.org/news/media-room/shipments-african-countries-broad-vaccination-against-malaria . Accessed: 19 April, 2024.
Carlson CJ, Bannon E, Mendenhall E, Newfield T, Bansal S. Rapid range shifts in African Anopheles mosquitoes over the last century. Biol Lett. 2023;19:20220365.
pubmed: 36789530
pmcid: 9929507
doi: 10.1098/rsbl.2022.0365
GAVI. Climate change causes malaria cases to triple in northwest Pakistan. Geneva, GAVI; 2024. https://www.gavi.org/vaccineswork/climate-change-causes-malaria-cases-triple-northwest-pakistan#:~:text=The%20World%20Malaria%20Report%20of,to%20500%20000%20in%202021.%22 . Accessed: 28 August, 2024.
Chalon S, Chughlay MF, Abla N, Marie Tchouatieu A, Haouala A, Hutter B, et al. Unanticipated CNS safety signal in a placebo-controlled, randomized trial of co-administered atovaquone-proguanil and amodiaquine. Clin Pharmacol Ther. 2022;111:867–77.
pubmed: 34453327
doi: 10.1002/cpt.2404
Liverpool School of Tropical Medicine. MiMBa Pregnancy Registry. Rockville Pike, National Library of Medicine; 2021. https://clinicaltrials.gov/study/NCT04825782 . Accessed: 19 April, 2024.
Acharya J, Harwani D. Changing pattern of severe manifestations of Plasmodium falciparum and Plasmodium vivax malaria: a retrospective study from Bikaner, India. J Vector Borne Dis. 2022;59:259–64.
pubmed: 36511043
doi: 10.4103/0972-9062.342396
Hawadak J, Dongang Nana RR, Singh V. Global trend of Plasmodium malariae and Plasmodium ovale spp. malaria infections in the last two decades (2000–2020): a systematic review and meta-analysis. Parasit Vectors. 2021;14:297.
pubmed: 34082791
pmcid: 8173816
doi: 10.1186/s13071-021-04797-0
UK Health Security Agency. Imported malaria in the UK: statistics. London, UK Government; 2023. https://www.gov.uk/government/publications/imported-malaria-in-the-uk-statistics . Accessed: 22 April, 2024.
Gilead Sciences Inc. Highlights of prescribing information: Sunlenca® (lenacapavir) tablets, for oral use; Sunlenca® (lenacapavir) injection, for subcutaneous use. Foster City, Gilead Sciences Inc; 2022. https://www.gilead.com/-/media/files/pdfs/medicines/hiv/sunlenca/sunlenca_pi.pdf . Accessed: 22 April, 2024.
Obebe OO, Olajuyigbe OO, Falohun OO. Prevalence of asymptomatic Plasmodium falciparum infection in pregnant women in Nigeria: a systematic review and meta-analysis. Ann Parasitol. 2020;66:283–94.
pubmed: 33126296
Kassie GA, Azeze GA, Gebrekidan AY, Lombebo AA, Adella GA, Haile KE, et al. Asymptomatic malaria infection and its associated factors among pregnant women in Ethiopia; a systematic review and meta-analysis. Parasite Epidemiol Control. 2024;24: e00339.
pubmed: 38323191
pmcid: 10844853
doi: 10.1016/j.parepi.2024.e00339
Jaen-Sanchez N, Gonzalez-Azpeitia G, Carranza-Rodriguez C, Manwere N, Garay-Sanchez P, Vallejo-Torres L, et al. Increased peripartum mortality associated with maternal subclinical malaria in Mozambique. Malar J. 2023;22:182.
pubmed: 37309000
pmcid: 10258955
doi: 10.1186/s12936-023-04613-3
Rouamba T, Samadoulougou S, Ouedraogo M, Hien H, Tinto H, Kirakoya-Samadoulougou F. Asymptomatic malaria and anaemia among pregnant women during high and low malaria transmission seasons in Burkina Faso: household-based cross-sectional surveys in Burkina Faso, 2013 and 2017. Malar J. 2021;20:211.
pubmed: 33933072
pmcid: 8088076
doi: 10.1186/s12936-021-03703-4
Muthiani Y, Hunter PJ, Nasanen-Gilmore PK, Koivu AM, Isojarvi J, Luoma J, et al. Antenatal interventions to reduce risk of low birth weight related to maternal infections during pregnancy. Am J Clin Nutr. 2023;117(Suppl 2):S118–33.
pubmed: 37331759
doi: 10.1016/j.ajcnut.2023.02.025
Gutman JR, Thwing J, Mwesigwa J, McElroy PD, Robertson M. Routine healthcare facility- and antenatal care-based malaria surveillance: challenges and opportunities. Am J Trop Med Hyg. 2023;108:4–7.
pubmed: 35895587
doi: 10.4269/ajtmh.22-0182
Waltmann A, McQuade ETR, Chinkhumba J, Operario DJ, Mzembe E, Itoh M, et al. The positive effect of malaria IPTp-SP on birthweight is mediated by gestational weight gain but modifiable by maternal carriage of enteric pathogens. EBioMedicine. 2022;77: 103871.
pubmed: 35217408
pmcid: 8866062
doi: 10.1016/j.ebiom.2022.103871
Duffey M, Blasco B, Burrows JN, Wells TNC, Fidock DA, Leroy D. Assessing risks of Plasmodium falciparum resistance to select next-generation antimalarials. Trends Parasitol. 2021;37:709–21.
pubmed: 34001441
pmcid: 8282644
doi: 10.1016/j.pt.2021.04.006
Figueroa-Romero A, Pons-Duran C, Gonzalez R. Drugs for intermittent preventive treatment of malaria in pregnancy: current knowledge and way forward. Trop Med Infect Dis. 2022;7:152.
pubmed: 36006244
pmcid: 9416188
doi: 10.3390/tropicalmed7080152
Tarning J, Lindegardh N, Lwin KM, Annerberg A, Kiricharoen L, Ashley E, et al. Population pharmacokinetic assessment of the effect of food on piperaquine bioavailability in patients with uncomplicated malaria. Antimicrob Agents Chemother. 2014;58:2052–8.
pubmed: 24449770
pmcid: 4023753
doi: 10.1128/AAC.02318-13
Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother. 2000;44:697–704.
pubmed: 10681341
pmcid: 89749
doi: 10.1128/AAC.44.3.697-704.2000
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry: food-effect bioavailability and fed bioequivalence studies. Rockville, U.S. Food and Drug Administration; 2002. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/food-effect-bioavailability-and-fed-bioequivalence-studies . Accessed: 14 September, 2023.
Hai TN, Hietala SF, Van Huong N, Ashton M. The influence of food on the pharmacokinetics of piperaquine in healthy Vietnamese volunteers. Acta Trop. 2008;107:145–9.
pubmed: 18585670
doi: 10.1016/j.actatropica.2008.05.013
Frueh L, Li Y, Mather MW, Li Q, Pou S, Nilsen A, et al. Alkoxycarbonate ester prodrugs of preclinical drug candidate ELQ-300 for prophylaxis and treatment of malaria. ACS Infect Dis. 2017;3:728–35.
pubmed: 28927276
pmcid: 5947850
doi: 10.1021/acsinfecdis.7b00062
Miley GP, Pou S, Winter R, Nilsen A, Li Y, Kelly JX, et al. ELQ-300 prodrugs for enhanced delivery and single-dose cure of malaria. Antimicrob Agents Chemother. 2015;59:5555–60.
pubmed: 26124159
pmcid: 4538462
doi: 10.1128/AAC.01183-15
Stickles AM, Smilkstein MJ, Morrisey JM, Li Y, Forquer IP, Kelly JX, et al. Atovaquone and ELQ-300 combination therapy as a novel dual-site cytochrome bc1 inhibition strategy for malaria. Antimicrob Agents Chemother. 2016;60:4853–9.
pubmed: 27270285
pmcid: 4958223
doi: 10.1128/AAC.00791-16
Smilkstein MJ, Pou S, Krollenbrock A, Bleyle LA, Dodean RA, Frueh L, et al. ELQ-331 as a prototype for extremely durable chemoprotection against malaria. Malar J. 2019;18:291.
pubmed: 31455339
pmcid: 6712883
doi: 10.1186/s12936-019-2921-9
Stickles AM, Ting LM, Morrisey JM, Li Y, Mather MW, Meermeier E, et al. Inhibition of cytochrome bc1 as a strategy for single-dose, multi-stage antimalarial therapy. Am J Trop Med Hyg. 2015;92:1195–201.
pubmed: 25918204
pmcid: 4458825
doi: 10.4269/ajtmh.14-0553
Siregar JE, Kurisu G, Kobayashi T, Matsuzaki M, Sakamoto K, Mi-ichi F, et al. Direct evidence for the atovaquone action on the Plasmodium cytochrome bc1 complex. Parasitol Int. 2015;64:295–300.
pubmed: 25264100
doi: 10.1016/j.parint.2014.09.011
Koller R, Mombo-Ngoma G, Grobusch MP. The early preclinical and clinical development of ganaplacide (KAF156), a novel antimalarial compound. Expert Opin Investig Drugs. 2018;27:803–10.
pubmed: 30223692
doi: 10.1080/13543784.2018.1524871
Kublin JG, Murphy SC, Maenza J, Seilie AM, Jain JP, Berger D, et al. Safety, Pharmacokinetics, and causal prophylactic efficacy of KAF156 in a Plasmodium falciparum human infection study. Clin Infect Dis. 2021;73:e2407–14.
pubmed: 32644127
doi: 10.1093/cid/ciaa952
Kuhen KL, Chatterjee AK, Rottmann M, Gagaring K, Borboa R, Buenviaje J, et al. KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission. Antimicrob Agents Chemother. 2014;58:5060–7.
pubmed: 24913172
pmcid: 4135840
doi: 10.1128/AAC.02727-13
Courlet P, Wilkins JJ, Oeuvray C, Gao W, Khandelwal A. Semi-mechanistic population pharmacokinetic/pharmacodynamic modeling of a Plasmodium elongation factor 2 inhibitor cabamiquine for prevention and cure of malaria. Antimicrob Agents Chemother. 2023;67: e0089123.
pubmed: 37966273
doi: 10.1128/aac.00891-23
McLellan JL, Hanson KK. Translation inhibition efficacy does not determine the Plasmodium berghei liver stage antiplasmodial efficacy of protein synthesis inhibitors. bioRxiv. 2023;12.07.570699. (pre-print)
Stadler E, Maiga M, Friedrich L, Thathy V, Demarta-Gatsi C, Dara A, et al. Propensity of selecting mutant parasites for the antimalarial drug cabamiquine. Nat Commun. 2023;14:5205.
pubmed: 37626093
pmcid: 10457284
doi: 10.1038/s41467-023-40974-8
van der Plas JL, Kuiper VP, Bagchus WM, Bodding M, Yalkinoglu O, Tappert A, et al. Causal chemoprophylactic activity of cabamiquine against Plasmodium falciparum in a controlled human malaria infection: a randomised, double-blind, placebo-controlled study in the Netherlands. Lancet Infect Dis. 2023;23:1164–74.
pubmed: 37414066
doi: 10.1016/S1473-3099(23)00212-8
LaMonte G, Lim MY, Wree M, Reimer C, Nachon M, Corey V, et al. Mutations in the Plasmodium falciparum cyclic amine resistance locus (PfCARL) confer multidrug resistance. mBio. 2016;7:e00696-16.
Magistrado PA, Corey VC, Lukens AK, LaMonte G, Sasaki E, Meister S, et al. Plasmodium falciparum cyclic amine resistance locus (PfCARL), a resistance mechanism for two distinct compound classes. ACS Infect Dis. 2016;2:816–26.
pubmed: 27933786
pmcid: 5109296
doi: 10.1021/acsinfecdis.6b00025
Kuemmerle A, Gossen D, Janin A, Stokes A, Abla N, Szramowska M, et al. Randomized, placebo-controlled, double-blind phase I trial of co-administered pyronaridine and piperaquine in healthy adults of sub-Saharan origin. Clin Transl Sci. 2024;17: e13738.
pubmed: 38594824
pmcid: 11004265
doi: 10.1111/cts.13738
Hoglund RM, Workman L, Edstein MD, Thanh NX, Quang NN, Zongo I, et al. Population pharmacokinetic properties of piperaquine in falciparum malaria: an individual participant data meta-analysis. PLoS Med. 2017;14: e1002212.
pubmed: 28072872
pmcid: 5224788
doi: 10.1371/journal.pmed.1002212
Morris CA, Lopez-Lazaro L, Jung D, Methaneethorn J, Duparc S, Borghini-Fuhrer I, et al. Drug-drug interaction analysis of pyronaridine/artesunate and ritonavir in healthy volunteers. Am J Trop Med Hyg. 2012;86:489–95.
pubmed: 22403324
pmcid: 3284369
doi: 10.4269/ajtmh.2012.11-0558
Jittamala P, Pukrittayakamee S, Ashley EA, Nosten F, Hanboonkunupakarn B, Lee SJ, et al. Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects. Antimicrob Agents Chemother. 2015;59:505–13.
pubmed: 25385096
doi: 10.1128/AAC.03829-14
European Medicines Agency. Eurartesim European public assessment report. Amsterdam, EMA; 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/eurartesim# . Accessed: 2 February, 2023.
Bailly C. Pyronaridine: an update of its pharmacological activities and mechanisms of action. Biopolymers. 2021;112: e23398.
pubmed: 33280083
doi: 10.1002/bip.23398
Drugbank Online. Piperaquine. Edmonton, OMx Personal Health Analytics Inc; 2023. https://go.drugbank.com/drugs/DB13941 . Accessed: 2 February, 2023.
Drugbank Online. Pyronaridine. Edmonton, OMx Personal Health Analytics Inc; 2023. https://go.drugbank.com/drugs/DB12975 . Accessed: 2 February, 2023.
Wu RL, Idris AH, Berkowitz NM, Happe M, Gaudinski MR, Buettner C, et al. Low-dose subcutaneous or intravenous monoclonal antibody to prevent malaria. N Engl J Med. 2022;387:397–407.
pubmed: 35921449
pmcid: 9806693
doi: 10.1056/NEJMoa2203067
Williams KL, Guerrero S, Flores-Garcia Y, Kim D, Williamson KS, Siska C, et al. A candidate antibody drug for prevention of malaria. Nat Med. 2024;30:117–29.
pubmed: 38167935
pmcid: 10803262
doi: 10.1038/s41591-023-02659-z
European Medicines Agency. Medicines assessed under the ‘EU-M4all’ procedure. Amsterdam, European Medicines Agency; 2024. https://www.ema.europa.eu/en/partners-networks/international-activities/medicines-assessed-under-eu-m4all-procedure#:~:text=The%20European%20Medicines%20Agency%20(EMA,or%20'EU%2DM4all '. Accessed: 22 April, 2024.
Swissmedic. Swissmedic procedure for scientific advice and Marketing Authorisation for Global Health Products (MAGHP). Bern, Swissmedic; 2023. https://www.swissmedic.ch/swissmedic/en/home/about-us/development-cooperation/marketing-authorisation-for-global-health-products.html . Accessed: 22 April, 2024.
WHO. Prequalification of medical products. Geneva, World Health Organization, 2023. https://extranet.who.int/prequal/ . Accessed: 22 April, 2024.
Thwing J, Williamson J, Cavros I, Gutman JR. Systematic review and meta-analysis of seasonal malaria chemoprevention. Am J Trop Med Hyg. 2024;110:20–31.
pubmed: 38081050
doi: 10.4269/ajtmh.23-0481
malERA Refresh Consultative Panel on Combination Interventions Modelling. malERA: An updated research agenda for combination interventions and modelling in malaria elimination and eradication. PLoS Med. 2017;14: e1002453.
doi: 10.1371/journal.pmed.1002453